RecruitingNot ApplicableNCT06264427

Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland


Sponsor

Steno Diabetes Center Greenland

Enrollment

1,000 participants

Start Date

Jul 15, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: * Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: * Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Type 2 diabetes and/or morbid obesity (BMI \>40)
  • Over 18 years old

Exclusion Criteria1

  • Does not speak either English, Danish or Greenlandic

Interventions

GENETICWhole genome sequencing

Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.

DIAGNOSTIC_TESTVAGUS

To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN

DIAGNOSTIC_TESTNightOwl

Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.

DEVICECPAP

Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).


Locations(1)

Steno Diabetes Center Greenland, Queen Ingrids Hospital

Nuuk, Sermersooq, Greenland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06264427


Related Trials